Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Q3 Net Loss Shrinks on Sharp Cost Cuts

NEW YORK (GenomeWeb News) – Vermillion yesterday reported no revenue for its third quarter ended Sept. 30, yet the firm managed to cut its net loss by 27 percent.
The firm, which changed its name in August to Vermillion from Ciphergen Biosystems, had no revenue for the quarter after selling its proteomics tools business to Bio-Rad Laboratories a year ago. The company had revenues of $4.7 million in the third quarter of 2006.
Vermillion cut its net loss to $5.1 million from $7 million year over year, due primarily to a drop in its sales and marketing costs to $516,000 from $3.2 million.
The firm’s R&D expenses also dropped 24 percent to $2.2 million from $2.9 million.
In addition to changing its name during the quarter, Vermillion also raised $20.6 million in a private placement. It intends to use the funds to support clinical studies on a variety of diagnostic tests it is developing.
Vermillion finished the quarter with $19.5 million in cash and cash equivalents.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.